EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation

Background/Aim: The EZH2 complex is involved in cellular proliferation and modulates the immune response in cancer. Less is known about the importance of EZH2 in precancerous lesions such as oral leukoplakia (OL). The aim of the study was to explore the association between EZH2 expression, immune activation, and cancer transformation in OL. Patients and Methods: Analyses were retrospectively performed on nine OL cases that had undergone transformation to oral squamous cell carcinoma (OSCC; OL-ca) and nine that had not undergone transformation (OL-non). EZH2-expressing cells, CD3+ and CD8+ T cells, and CD1a+ Langerhans cells were visualized with immunohistofluorescence and counted. Results: A moderate positive correlation between CD3− and EZH2-expressing and CD8− and EZH2-expressing cells in the epithelium was found (r=0.57, p=0.01; r=0.59, p=0.01). The number of EZH2-expressing cells in the epithelium of OL-ca was significantly higher compared to OL-non (p=0.0002). Cancer-free survival rates differed significantly between patients with EZH2high compared to EZH2low expression (p=0.001). EZH2high expression in OL epithelium was associated with a 13-fold higher risk for developing OSCC (HR=12.8). Conclusion: EZH2 expression in oral epithelium predicts OSCC transformation of OL and correlates with the level of T-cell infiltration.

[1]  Yufei Wang,et al.  CD8+ T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy , 2022, Immunology.

[2]  M. Sperandio,et al.  Oral epithelial dysplasia grading: comparing the binary system to the traditional 3-tier system, an actuarial study with malignant transformation as outcome. , 2022, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  Wei Zhang,et al.  Influence of PD-1/PD-L1 on immune micro-environment in oral leukoplakia and oral squamous cell carcinomas. , 2022, Oral diseases.

[4]  Giacomo Cavalli,et al.  Mechanisms of Polycomb group protein function in cancer , 2022, Cell Research.

[5]  Z. Shang,et al.  Burden of Oral Cancer on the 10 Most Populous Countries from 1990 to 2019: Estimates from the Global Burden of Disease Study 2019 , 2022, International journal of environmental research and public health.

[6]  Yan Sun,et al.  Comprehensive Analysis of the Expression Characteristics of the Enhancer of the Zeste Homolog 2 Gene in Pan-Cancer , 2021, Frontiers in Genetics.

[7]  Guo-Qing Wu,et al.  The functions of EZH2 in immune cells: Principles for novel immunotherapies , 2020, Journal of leukocyte biology.

[8]  João Caramês,et al.  Malignant transformation rate of oral leukoplakia-systematic review. , 2020, Oral surgery, oral medicine, oral pathology and oral radiology.

[9]  S. Warnakulasuriya,et al.  Oral potentially malignant disorders: A comprehensive review on clinical aspects and management. , 2020, Oral oncology.

[10]  Yanni Chen,et al.  An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response , 2019, Cancer Research.

[11]  Tao Yu,et al.  Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3 , 2018, Journal of Experimental Medicine.

[12]  M. Sung,et al.  Ezh2 Regulates Activation-Induced CD8+ T Cell Cycle Progression via Repressing Cdkn2a and Cdkn1c Expression , 2018, Front. Immunol..

[13]  J. Issa,et al.  Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity , 2017, Nature Communications.

[14]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[15]  X. Mo,et al.  Circulating histones for predicting prognosis after cardiac surgery: a prospective study. , 2016, Interactive cardiovascular and thoracic surgery.

[16]  D. Pasini,et al.  Emerging roles for Polycomb proteins in cancer. , 2016, Current opinion in genetics & development.

[17]  F. Ginhoux,et al.  The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin , 2015, Nature Immunology.

[18]  M. Jontell,et al.  Presence of CD3-positive T-cells in oral premalignant leukoplakia indicates prevention of cancer transformation. , 2015, Anticancer research.

[19]  P. Vrtačnik,et al.  Epigenetic mechanisms in bone , 2014, Clinical chemistry and laboratory medicine.

[20]  T. Speed,et al.  Distinct Epigenetic Signatures Delineate Transcriptional Programs during Virus-Specific CD8 T Cell Differentiation , 2014 .

[21]  Yutaka Suzuki,et al.  The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. , 2013, Immunity.

[22]  Susan M. Kaech,et al.  Transcriptional control of effector and memory CD8+ T cell differentiation , 2012, Nature Reviews Immunology.

[23]  T. Liloglou,et al.  DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer , 2012, Clinical chemistry and laboratory medicine.

[24]  K. Heichman,et al.  DNA methylation biomarkers and their utility for solid cancer diagnostics , 2012, Clinical chemistry and laboratory medicine.

[25]  M. Fraga,et al.  Global DNA hypomethylation in cancer: review of validated methods and clinical significance , 2012, Clinical chemistry and laboratory medicine.

[26]  Ruedi Aebersold,et al.  Molecular architecture of human polycomb repressive complex 2 , 2012, eLife.

[27]  E. Telemo,et al.  Langerhans Cells and T Cells Sense Cell Dysplasia in Oral Leukoplakias and Oral Squamous Cell Carcinomas – Evidence for Immunosurveillance , 2012, Scandinavian journal of immunology.

[28]  L. Mao,et al.  EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia , 2011, Cancer Prevention Research.

[29]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[30]  A. Keating,et al.  Natural Killer Cells for Cancer Immunotherapy , 2011 .

[31]  M. Gilliet,et al.  Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses , 2010, Annals of the New York Academy of Sciences.

[32]  A. Chow.  Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells , 2010 .

[33]  D. Gibbings,et al.  CD4 and CD8: an inside‐out coreceptor model for innate immune cells , 2009, Journal of leukocyte biology.

[34]  Junli Zhao,et al.  Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia , 2009, Clinical chemistry and laboratory medicine.

[35]  M. van Lohuizen,et al.  Stem cell regulation by polycomb repressors: postponing commitment. , 2008, Current opinion in cell biology.

[36]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[37]  Artur Ferreira,et al.  Oral squamous cell carcinoma: review of prognostic and predictive factors. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[38]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[39]  I. Gannot,et al.  Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma , 2002, British Journal of Cancer.

[40]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.